Dr. Stephens is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2000 Circle of Hope Dr
Salt Lake City, UT 84112Phone+1 801-585-0236Fax+1 801-585-0309
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2011 - 2014- Ohio State University HospitalResidency, Internal Medicine, 2009 - 2010
Kansas City University of Medicine and Biosciences College of Osteopathic MedicineClass of 2007
Certifications & Licensure
NC State License 2023 - 2025
ID State License 2021 - 2024
UT State License 2014 - 2024
OH State License 2007 - 2016
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma Start of enrollment: 2014 Dec 29
- Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma Start of enrollment: 2015 Mar 11
- Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2017 Nov 27
- Join now to see all
Publications & Presentations
PubMed
- 8 citationsImpact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy.Reem Karmali, Rushad Machhi, Narendranath Epperla, Geoffrey Shouse, Jason Romancik
Blood Advances. 2024-05-28 - 5 citationsHypertension treatment for patients receiving ibrutinib: a multicenter retrospective study.Laura Samples, Jenna Voutsinas, Bita Fakhri, Sirin Khajavian, Stephen Spurgeon
Blood Advances. 2024-05-14 - 13 citationsFollow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.Jennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, Cecelia Miller, Nyla A Heerema
Blood. 2024-04-18
Press Mentions
NCCN Clinical Practice Guidelines in Oncology: 2023 UpdatesMay 19th, 2023- CLL: Black Patients Die Sooner Than White PatientsMay 8th, 2023
- Huntsman Cancer Institute March Research HighlightsApril 5th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
